Mereo BioPharma Group Executives Conduct Share Sales
| Reporter Name | Relationship | Type | Amount | SEC Filing |
|---|---|---|---|---|
| Hughes-Wilson Alexandra | Officer | Sell | $637,203 | Form 4 |
| Fox Christine Ann | Chief Financial Officer | Sell | $121,692 | Form 4 |
| Sermon Charles | General Counsel | Sell | $133,050 | Form 4 |
| Lewicki John A. | Chief Scientific Officer | Sell | $69,476 | Form 4 |
| Scots-Knight Denise | Chief Executive Officer | Sell | $381,422 | Form 4 |
Several officers of Mereo BioPharma Group plc have recently sold shares of the company, according to SEC Form 4 filings.
Alexandra Hughes-Wilson, an officer, sold 148,110 American Depositary Shares representing Ordinary Shares on September 12 and 13, 2024, at weighted average prices of $4.4727 and $4.221, totaling $637,203. Following these transactions, Hughes-Wilson directly owns 50,475 shares.
Christine Ann Fox, Chief Financial Officer, sold 28,286 shares over the same two days, with sales totaling $121,692. Post-sale, Fox directly owns 89,285 shares.
Charles Sermon, General Counsel, sold 30,926 shares for a total of $133,050, and now directly owns 219,061 shares.
John A. Lewicki, Chief Scientific Officer, sold 16,149 shares, totaling $69,476. Following the transactions, Lewicki directly owns 78,630 shares and indirectly owns 14,196 shares through The Lewicki Family Living Trust.
Denise Scots-Knight, Chief Executive Officer and Director, sold 88,657 shares, totaling $381,422. Scots-Knight directly owns 808,921 shares following the transactions.